Clinical Trials
16 trialsNCT03291444 2024-03-15
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Phase 1 Unknown
NCT06238336 2024-02-02
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
Shanxi Bethune Hospital
Phase 2/3 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT04790747 2021-03-10
Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
Zhejiang University
Phase 1/2 Unknown
NCT04692948 2021-03-08
TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase NA Unknown
NCT02186860 2021-02-10
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown
NCT04287309 2020-02-27
CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS
Zhejiang University
Unknown
NCT04206943 2020-01-27
ISIKOK-19
Acibadem University
Phase 1/2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03598179 2019-08-07
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02965092 2019-05-10
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Phase 1/2 Unknown
NCT03881774 2019-03-21
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Henan Cancer Hospital
Phase 1 Unknown
NCT02819583 2016-10-25
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02851589 2016-08-01
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02315118 2016-06-22
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
National University Hospital, Singapore
Phase 1/2 Unknown
NCT01864902 2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2 Unknown